Adding Lilly’s new drug to Zepbound helped people lose more weight — but there were more side effects
The pharma giant is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes.
The pharma giant is working on an experimental amylin drug to see if it can help people lose weight and manage their diabetes. This story matters for Finance & Markets readers tracking finance. Reported by marketwatch.com. Read the full original at the source link below.
Originally reported by marketwatch.com. InvestorsWire curates and briefs the finance & markets stories that matter. Our editorial policy →